Introduction
============

Enteric infections caused by pathogens, like Enterotoxigenic *Escherichia coli* (ETEC), have a significant negative effect on neonatal survival and animal health in swine production ([@B36]; [@B57]; [@B15]). Animal infants infected by pathogenic bacteria often suffer from persistent diarrhea and serious inflammation ([@B15]; [@B60]). Prolonged inflammation of the intestinal tract leads to substantial destruction of the intestinal epithelia, resulting in malnutrition and impairing the early growth of infants ([@B62]; [@B61]; [@B39]). Application of antibiotics in formula feed is well established method and can improve growth rates of piglets ([@B48]). However, abuse of antibiotics is contributing to the high level of drug resistance in microbial communities and rising concerns regarding human health ([@B62]; [@B36]; [@B22]; [@B35]). An alternative to antibiotics is lysozyme, an enzyme and natural broad-spectrum bactericide commonly found in tears, saliva, and milk, and that is a vitally important immune system activator under physiological conditions ([@B27], [@B29]; [@B19]). During bacterial infection of the intestine, mammalian Paneth cells are also able to secrete lysozyme via secretory autophagy to maintain intestinal homeostasis ([@B3]).

Breast milk contains lysozyme (\<0.065 μg/mL), along with lactoferrin and secretory IgA (SIgA), which greatly aid the establishment of beneficial gut microbiota in newborns ([@B29]; [@B37]). Lysozyme functions by cleaving the β-1,4-glycosidic bond between *N*-acetylmuramic acid and *N*-acetylglucosamine residues of the bacterial peptidoglycan, causing a loss of cellular membrane integrity and cell lysis ([@B36]; [@B22]). Lysozyme was reported to be more effective against Gram-positive bacteria ([@B30]; [@B50]; [@B13]), and it may also indirectly affect several Gram-negative bacterial species ([@B27],[@B28]). Previous studies revealed that lysozyme promotes the beneficial microbe community and reduces detrimental microbes within gut microbial communities ([@B17]; [@B29]). Lysozyme could be effective against a wide range of gastrointestinal pathogens, such as *Listeria monocytogenes, Clostridium perfringens, Candida* spp., and *Helicobacter pylori in vitro* ([@B4]; [@B61]). Bacterial sensitivity to lysozyme is also due to the activation of innate components of the immune system, such as increased neutrophil activation during inflammation ([@B40]; [@B15]). It has been reported that lysozyme may possess an anti-inflammatory effect via inhibiting JNK phosphorylation ([@B46]). Furthermore, lysozyme is capable of enhancing intestinal SIgA secretion, cause macrophage activation, and promote rapid clearance of bacterial pathogens ([@B19]; [@B57]; [@B40]).

Recent studies reported that lysozyme sourced from chicken eggs showed significant advances in improving growth performance, intestinal morphology, gut microbiota composition, and immunity of piglets ([@B31]; [@B36], [@B37]; [@B38]; [@B57]). For instance, weaned piglets received a hen-egg white lysozyme treatment shown better intestinal growth and development, as well as decreased ETEC counts on the intestinal mucosa and serum proinflammatory cytokines ([@B34]). Moreover, lysozyme produced by transgenic animals and structurally modified lysozyme was shown to possess significant antimicrobial properties against pathogens like ETEC in piglets ([@B33]; [@B27]; [@B4]; [@B49]; [@B34]; [@B24]). Piglets that consumed lysozyme-transgenic goats' milk (containing human lysozyme at 67% of the concentration in human breast milk) showed better intestinal morphology and fewer total coliform counts ([@B4]).

Gut microbiota plays multiple roles in animal growth and health, including energy extraction from the diet, gut barrier function and immunity as well as growth performance ([@B45]; [@B10]). Increasing evidence suggests that maternal diet during pregnancy modifies an offspring's microbiota composition and intestinal development in a long-term manner ([@B8]; [@B6]). Nutritional intervention on sows with additives results in greater neonatal survival and infant health ([@B37]). However, none of these studies above provided a systematic overview of the effects of lysozyme on sow gut microbiota and its potential interactions with immune systems and milk composition. Given this, in the present study, 24 pregnant sows were assigned to a control group without supplementation and two treatments with 0.5 kg/t and 1.0 kg/t lysozyme additives provided in formula feed (*n* = 8, per group). After the 21-day supplementation, the effects of lysozyme on sow's gut microbiota, milk metabolite profile, and serum biochemical indices were systematically investigated and associations among them mediated by lysozyme treatment were also revealed for the first time.

Materials and Methods {#s1}
=====================

Animals and Ethics Statement
----------------------------

All procedures involving animals were carried out in accordance with guidelines for animal studies issued by the Animal Care and Use Committee of the Institute of Subtropical Agriculture, Chinese Academy of Sciences ([@B64]). Modified hen-egg white lysozyme additives were obtained from Shanghai E. K. M Biotechnology Co. Ltd., Shanghai, China. A total of 24 multiparous hybrid pregnant sows (Landrace × Yorkshire) with an average parity of 4.67 ± 1.50 were selected to this study and then randomly assigned to three groups (*n* = 8 per treatment), including a control group (CN) without supplementation and two treatments with 0.5 kg/t (LA) and 1.0 kg/t (LB) lysozyme provided in formula feed. Lysozyme was pre-mixed in formula feeds and the daily intake of every sow is about 10 kg (For lysozyme, about 5 g in LA group and 10 g in LB group every day). The present study started 24 days before the expected date of confinement. Sows did not have diseases like diarrhea and had never received antibiotics before the study. Lysozyme supplementation continued for 21 days till prenatal fasting. Milk from all investigated sows were collected on the due date.

Sample Collection and Processing
--------------------------------

After the 21-day supplementation, fresh feces from each individual were collected on the same day using 5 mL sterile centrifugal tubes, immediately frozen in liquid nitrogen, and stored at -80°C until DNA extraction. After the 21-day supplementation, the sows were restrained for blood sampling and approximately 5 mL blood was collected in a vacuum tube from the sow's auricular vein and directly centrifuged at 1500 × *g* for 15 min. The supernatant of each sample was then divided into subsamples and stored at -20°C until analysis. On parturition day, milk from each individual was collected with 5 mL sterile centrifugal tubes and immediately frozen at -20°C until further analysis.

Microbiota Analysis Based on 16S RNA High-Throughput Sequencing
---------------------------------------------------------------

Eight fecal samples from sows in each group (*n* = 8 per treatment) were chosen for microbiota analysis and total bacterial DNA was extracted from approximately 0.25 g of feces using a QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The diversity and composition of the bacterial community were determined by high-throughput sequencing of the microbial 16S rRNA genes. The V4 hypervariable region of the 16S rRNA genes was PCR amplified using 515F: 5′-GTGCCAGCMGCCGCGGTAA-3′ and 806R: 5′-GGACTACHVGGGTWTCTAAT-3′ primers, Illumina adaptors, and molecular barcodes. Paired-end sequencing was performed on the Illumina HiSeq 2500 platform (Novogene, Beijing, China). Raw 16S data sequences were obtained before being screened and assembled using the QIIME (v1.9.0) ([@B5]) and FLASH software packages. UPARSE (v7.0.1001) ([@B12]) was used to analyze the high-quality sequences and determine OTUs. Subsequently, high-quality sequences were aligned against the SILVA reference database^[1](#fn01){ref-type="fn"}^ and clustered into OTUs at a 97% similarity level using the UCLUST algorithm^[2](#fn02){ref-type="fn"}^. Each OTU was assigned to a taxonomic level with the Ribosomal Database Project Classifier program v2.20^[3](#fn03){ref-type="fn"}^. The assembled HiSeq sequences obtained in the present study were submitted to the NCBI's Sequence Read Archive (SRA, No. PRJNA415259) for open access.

Metagenomic Prediction and Metabolic Phenotype Analysis
-------------------------------------------------------

Functional metagenomes of all samples were predicted using PICRUSt v1.1.3 ([@B18]). OTUs were determined according to the instructions provided in the Genome Prediction Tutorial for PICRUSt. Metagenomes^[4](#fn04){ref-type="fn"}^ were predicted from the copy number normalized 16S rRNA data in PICRUSt using the predict metagenomes.py script against the functional database of KEGG Orthology. Functional categories at different levels were computed with the script categorize by function.py. Functional differences within groups were explored using LEfSe and specific analysis was performed through the Galaxy server ([@B32]). Output files from the PICRUSt analysis were collected and analyzed by R software (v3.5.1) for further statistical interrogation and graphical depictions of all predicted functional datasets. BugBase^[5](#fn05){ref-type="fn"}^ was employed to predict organism-level microbiome phenotypes using 16S RNA datasets and mapping file according to the tutorial ([@B56]).

Serum Biochemical Indices and Immunoglobulins Analysis
------------------------------------------------------

Eight serum samples from each group (*n* = 8 per treatment) were chosen for further analysis of biochemical and immune indices. Serum parameters investigated in the present study included: total protein (TP), blood urea nitrogen (BUN), creatinine (CREA), cholesterol (CHO), triglycerides (TG), high- and low-density lipoprotein cholesterol (HDL-C, LDL-C), glucose (GLU), albumin (ALB), globulin (GLO), AST and ALT. All parameters were measured using the TBA-120FR biochemistry analyzer provided by the Biochemical Analysis Center of Hunan Normal University Hospital. IgG, IgM, and IgA were measured with enzyme-linked immunosorbent assay kits (Cusabio Biotech Co., Hubei, China) according to the manufacturer's instructions and previous research ([@B26]).

Untargeted Metabolomic Analysis
-------------------------------

Milk from sows with nearby delivery time (within 48 h, *n* = 6 per treatment) were chosen for untargeted metabolomic analysis based on the liquid chromatography--tandem mass spectrometry (LC--MS/MS) platform. Milk samples were slowly thawed at 4°C first, and then 100 μl of each sample was added to 400 μl pre-cooled methanol/acetonitrile (1:1, v/v), vortex mixed, stood at -20°C for 60 min, centrifuged at 14,000 × *g* for 20 min at 4°C, took the supernatant and vacuum dried. For mass spectrometry, 100 μl of acetonitrile aqueous solution (acetonitrile:water = 1:1, v/v) was reconstituted, vortexed, centrifuged at 14,000 × g for 5 min at 4°C, and supernatants were taken for further analysis on LC--MS/MS platform (Bioprofile Co. Ltd., Shanghai, China). Each sample was tested by positive ion and negative ion mode using electrospray ionization (ESI). Samples were separated by ultra performance liquid chromatography (UPLC) and analyzed by mass spectrometry using a Triple-TOF 5600 mass spectrometer (AB SCIEX). The raw data was converted to .mzXML format by ProteoWizard ([@B2]), and then the XCMS program ([@B47]) was used for peak alignment, retention time correction, and peak area extraction. Metabolomic data were analyzed with MetaboAnalyst v4.0 ([@B7]) online version^[6](#fn06){ref-type="fn"}^. Key metabolites were filtered by VIP scores and rules used in our previous research ([@B42]).

Statistical Analysis
--------------------

All statistical analyses were performed using SPSS 25.0 software (SPSS Inc., Chicago, IL, United States). Alpha and beta diversity were analyzed with QIIME (v1.7.0) and displayed with R software (v3.5.1) and details can be found in the legends of the corresponding figures and tables. The differences among groups were compared using one-way ANOVA and Tukey-Kramer multiple comparison tests. *P-*values \<0.05 were used to indicate statistical significance.

Results
=======

Lysozyme Significantly Altered the Diversity and Composition of Sow's Gut Microbiota
------------------------------------------------------------------------------------

Gut microbial diversity, evidenced by the Shannon index, showed a significant reduction in the 1.0 kg/t group compared to the control (*p* = 0.0014, [Figure 1A](#F1){ref-type="fig"}) and no remarkable differences were found in indicators of microbial richness (ACE and Chao1, [Supplementary Table 1](#SM1){ref-type="supplementary-material"}). The principal coordinate analysis (PCoA) based on Bray--Curtis dissimilarity revealed that microbiota showed obvious segregation from the control group to lysozyme-treated groups ([Figure 1B](#F1){ref-type="fig"}). In addition, non-metric multidimensional scaling (NMDS) plots of β-diversity weighted unifrac ([Figure 1C](#F1){ref-type="fig"}) also confirmed the differences between control and lysozyme-treated groups \[all *P* \< 0.05 by Anosim analysis and multi-response permutation procedure (MRPP)\]. Furthermore, an unweighted pair-group method with arithmetic mean (UPGMA) analysis based on weighted unifrac distances were applied and the phylogeny showed the relationships of all observed samples. The phylogeny revealed that *Firmicutes, Bacteroidetes, Proteobacteria, Fibrobacteres*, and *Spirochaetes* are the dominant bacteria in sow's gut microbiome ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}).

![Effects of different lysozyme levels on sow's gut microbiota. **(A)** The microbial alpha diversity (as accessed by Shannon index) based on whole OTU table. The distribution and density of samples are displayed in violin plot. Boxes represent the interquartile ranges, the inside black plots represent the median, and circles are outliers. *P*-values are from Wilcoxon rank sum test. **(B,C)** Principal coordinate analysis (PCoA) and non-metric multidimensional scaling (NMDS) analysis based on the OTU table. Significant *P*-values of Anosim and multi-response permutation procedure (MRPP) between groups emphasize the differences in microbial community structure. **(D)** LEfse analysis at different microbial taxonomic levels \[linear discriminant analysis (LDA) score = 3.5\]. **(E)** Heatmap tree shows genera significantly different among groups and their phylogenic relationships. The abundance profiles are expressed by z-scores, and genera were clustered based on Bray--Curtis distance in the clustering tree. **(F)** *T*-test bar plot of significantly differed species between groups. **(G,H)** Spearman's correlation networks based on genera profile. Control group **(G)** and 1.0 kg/t treated group **(H)** showed alterations in microbial relationships.](fmicb-10-00177-g001){#F1}

Further, variations in the microbial composition of all groups were explored. LEfSe analysis of the bacterial community was used to filter the significantly different OTUs among groups and the results showed that there exist dramatic differences in microbial composition between the 1.0 kg/t group and the control group ([Figure 1D](#F1){ref-type="fig"}). *Spirochaetes, Euryarchaeota*, and *Actinobacteria* significantly increased but *Firmicutes* showed a remarkable reduction in the 1.0 kg/t treated group compared with the control ([Table 1](#T1){ref-type="table"}). The heat map (according to the top 35 most different genera) shows the taxonomic distributions among each group ([Figure 1E](#F1){ref-type="fig"}). Specifically, *Escherichia coli* showed a dramatically dose-response reduction in both the 0.5 kg/t and 1.0 kg/t lysozyme-treated groups ([Figure 1F](#F1){ref-type="fig"}). Furthermore, *Lactobacillus amylovorus* showed a significant increase in the 0.5 kg/t group ([Figure 1F](#F1){ref-type="fig"}).

###### 

Changes in major microbial phylum of sow's gut microbiota after the 21-day lysozyme supplementation^1^.

  Taxonomy (%)     Control     0.5 kg/t     1.0 kg/t   *p*-Value
  ---------------- ----------- ------------ ---------- -----------
  Firmicutes       63.08^a^    59.27^a,b^   57.09^b^   0.033
  Bacteroidetes    26.79       31.07        30.02      0.141
  Spirochaetes     4.42^b^     4.95^b^      7.57^a^    0.011
  Proteobacteria   3.33        2.91         2.67       0.077
  Fibrobacteres    0.76        0.44         0.73       0.761
  Euryarchaeota    0.30^a,b^   0.14^b^      0.52^a^    0.010
  Actinobacteria   0.36^a,b^   0.30^b^      0.43^a^    0.023
  Cyanobacteria    0.34        0.30         0.37       0.418
  Tenericutes      0.34        0.31         0.30       0.549
  Elusimicrobia    0.05        0.06         0.08       0.279
  Others           0.23        0.25         0.24       0.806

1

Data were analyzed by one-way ANOVA followed by Tukey-Kramer multiple comparison tests.

a,b

Values within a row with different superscripts differ significantly at

p

\< 0.05.

To further determine the relationships among different microbes in the control and the 1.0 kg/t group, network analysis of gut microbiome was determined by calculating Spearman's correlation coefficients among all genera. The results revealed that lysozyme supplementation with 1.0 kg/t rebuilt interactions among different genera ([Figure 1H](#F1){ref-type="fig"}). Compared with the control ([Figure 1G](#F1){ref-type="fig"}), gut microbiota shaped by 1.0 kg/t lysozyme treatments had fewer cross-linking, more positive correlations and shorter interactions indicated by lower graph densities (GD) (0.0037 and 0. 0027 in the control and 1.0 kg/t group, respectively), lower average degree (AD) (1.64 and 1.17), lower network diameters (ND) (5 and 4), lower average path lengths (APL) (1.66 and 1.17), higher modularity (MD) (0.87 and 0.94), and higher cluster coefficients (CC) (0.48 and 0.66).

Lysozyme Shifted the Metabolic Functions of Sow's Gut Microbiota
----------------------------------------------------------------

To investigate further changes in microbial metabolic functions in gut microbiota driven by lysozyme treatment, Picrust was used to generate the metagenome based on 16S RNA sequencing results. The principal component analysis (PCA) based of KEGG annotation results revealed that the metabolic functions of sow's gut microbiota showed obvious segregation from the control group to lysozyme-treated groups ([Figure 2A](#F2){ref-type="fig"}). Furthermore, 80 pathways were found to significantly differ among groups at KEGG level 3, including those associated with cellular processes, environmental factors, genetic information processing, organismic systems, metabolism, and human diseases ([Supplementary Table 2](#SM1){ref-type="supplementary-material"}). LEfSe analysis of the KEGG annotation results was used to filter the significantly differed pathways among groups ([Figure 2B](#F2){ref-type="fig"}) and results showed that there exist dramatic differences in microbial composition between the 1.0 kg/t group and the control group ([Figure 2D](#F2){ref-type="fig"}), which is in line with variations in microbial structure ([Figure 1D](#F1){ref-type="fig"}--[F](#F1){ref-type="fig"}). In current study, microbial metabolism related pathways at KEGG Level 3 were specifically concerned and filtered. The heat map (according to the most different metabolism related pathways) showed the specific functional pathway distribution among each group ([Figure 2C](#F2){ref-type="fig"}). Moreover, pyrimidine metabolism, purine metabolism, and amino acid related enzymes were significantly upregulated in the 1.0 kg/t lysozyme-treated group ([Figure 2D](#F2){ref-type="fig"}).

![Lysozyme supplementation shifted the metabolic functions of sow's gut microbiota. **(A)** Principal components analysis (PCA) plot of functional profiles upon lysozyme supplementation. **(B)** LEfse analysis at different KEGG taxonomic levels \[linear discriminant analysis (LDA score = 2.0)\]. **(C)** Heatmap tree shows metabolism related pathway significantly different among groups at KEGG level 3 and their phylogenic relationships. **(D)** *T*-test bar plot of significantly differed pathways between 1.0 kg/t treated groups and control group at KEGG level 3.](fmicb-10-00177-g002){#F2}

Lysozyme Mediated Dose-Dependent Changes in Gut Microbial Metabolic Phenotypes
------------------------------------------------------------------------------

To determine the reported impact of lysozyme on Gram-positive bacteria, organism-level coverage of functional pathways and biologically interpretable phenotypes were predicted via BugBase, an algorithm that predicts organism-level coverage of functional pathways, as well as biologically interpretable phenotypes, such as oxygen tolerance, gram staining and pathogenic potential, within complex microbiomes using either whole-genome shotgun or marker gene sequencing data. Results showed that richness of anaerobic bacteria was significantly higher in 0.5 kg/t group than 1.0 kg/t group ([Figure 3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}). Results demonstrated that the richness of Gram-positive bacteria were significantly down-regulated by lysozyme treatments, while Gram-negative bacteria showed a significant increase ([Figure 3D,E](#F3){ref-type="fig"}). Further, mobile genetic elements and oxidative stress tolerance of gut microbiota were reduced by increased lysozyme level ([Figure 3F,H](#F3){ref-type="fig"}). Otherwise, lysozyme supplementation significantly increased biofilm formation in the lysozyme-treated groups ([Figure 3G,I](#F3){ref-type="fig"}).

![Variations in metabolic phenotypes of sow's microbiota driven by lysozyme treatment. These results were generated from BugBase online (<https://bugbase.cs.umn.edu/>). (**A**--**C)** Oxygen utilizing. **(D,E)** Gram bacterial classification. **(F)** Mobile-element containing. **(G)** Biofilm forming. **(H)** Oxidative stress tolerant. **(I)** Potential pathogenic risk. Discrete phenotype relative abundances were compared using pair-wise Mann--Whitney *U* tests with false discovery rate correction, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](fmicb-10-00177-g003){#F3}

Lysozyme Significantly Changed Sow Serum Immunity
-------------------------------------------------

To identify the impact of lysozyme on sow's immunity, serum biochemical indices and immunoglobulins were determined. Results showed that serum alanine transaminase (ALT) levels were significantly down-regulated by lysozyme treatment ([Figure 4B](#F4){ref-type="fig"}). Serum aspartate transaminase showed no difference among groups ([Figure 4A,C](#F4){ref-type="fig"}). Dietary lysozyme supplementation had no significant impact on serum metabolite profiles (e.g., HDL-c, LDL-c, TG, and BUN, [Supplementary Table 3](#SM1){ref-type="supplementary-material"}). For immunoglobulins, serum IgM levels were significantly higher in the 1.0 kg/t group compared with the control, while IgA levels were significantly lower in the 1.0 kg/t group ([Figure 4D](#F4){ref-type="fig"}--[F](#F4){ref-type="fig"}).

![Lysozyme mediated changes in serum indices and correlations with gut microbiota. **(A)** Serum aspartate transaminase (AST), **(B)** serum alanine transaminase (ALT), **(C)** AST/ALT ratio, **(D--F)**. Serum immunoglobulins, IgM **(D)**, IgA **(E)**, and IgG **(F)**. **(G)** Heatmap of the Spearman r correlations between the gut microbiota significantly modified serum biochemical makers after 21-day lysozyme supplementation. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 (following the Spearman correlation analysis). BUN, blood urea nitrogen; CREA, creatinine; TG, triglycerides; GLU, glucose; HDL-C, LDL-C, high- and low-density lipoprotein cholesterol; CHO, cholesterol; AST, aspartate transaminase; ALT, alanine transaminase; TP, total protein; ALB, albumin; GLO, globulin; A/G, albumin/globulin ratio.](fmicb-10-00177-g004){#F4}

To further explore the relationship between immunity and the altered gut microbiome driven by lysozyme treatment, Spearman's correlation coefficients between serum biochemical makers and immunoglobulins and major genera were calculated and visualized with heatmaps. Twelve genera, including *Prevotella, Ruminococcaceae UGG*, and *Bacteroides* showed significant correlations with IgA ([Figure 4G](#F4){ref-type="fig"}). *Ruminiclostridium 9* showed a significant positive relation with IgM. *Methanobrevibacter* showed a significantly negative relationship with AST, while *Lactobacillus* showed a significant positive correlation ([Figure 4G](#F4){ref-type="fig"}).

Variations in Sow's Milk Metabolite Profile Driven by Different Lysozyme Levels
-------------------------------------------------------------------------------

To evaluate the effects of lysozyme treatment on sow's milk, untargeted LC--MS/MS was applied to assess the metabolite profiles after the 21-day supplementation. PCA of metabolites cannot effectively distinguish the variations among groups ([Figure 5A](#F5){ref-type="fig"}), therefore, partial least squares - discriminant analysis (PLS-DA) and sparse partial least squares - discriminant analysis (sPLS-DA) were used ([Figure 5B,C](#F5){ref-type="fig"}). Both techniques revealed a distinct partition between lysozyme-treated groups and the control. The heat map (according to the most different metabolites) showed specific metabolite distributions within each group ([Figure 5D](#F5){ref-type="fig"}). Twenty metabolic makers were identified by PLS-DA including uridine 5′-diphosphate (UDP), UDP-[D]{.smallcaps}-glucuronate, acamprosate, and triethanolamine ([Figure 5E](#F5){ref-type="fig"}). In addition, 10 metabolites were filtered by sPLS-DA including succinate, [L]{.smallcaps}-glutamine, and UDP-[D]{.smallcaps}-glucuronate ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}). Given this, metabolites significantly differed among groups were filtered and combined via both PLS-DA and sPLS-DA ([Table 2](#T2){ref-type="table"}). Moreover, significant differences metabolites between the 1.0 kg/t and the control groups were also filtered via PLS-DA ([Supplementary Figure 3](#SM1){ref-type="supplementary-material"}) and metabolic makers were obtained ([Supplementary Table 4](#SM1){ref-type="supplementary-material"}). Milk metabolites such as [L]{.smallcaps}-glutamine, creatine and [L]{.smallcaps}-arginine showed significantly dose-dependent changes after treatment ([Figure 5](#F5){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

![Changes in sow's milk metabolite profile shaped by different lysozyme levels. **(A)** Principal components analysis (PCA) plot of metabolic profiles of sow's milk upon lysozyme supplementation. **(B,C)** Partial least squares - discriminant analysis (PLS-DA) score plot **(B)** and sparse partial least squares - discriminant analysis (sPLS-DA) plot **(C)** of metabolic profiles and the explained variances are shown in brackets. **(D)** Heatmap tree shows metabolite significantly different among groups and their phylogenic relationships. The abundance profiles are expressed by z-scores. **(E)** Important features identified by PLS-DA. The colored boxes on the right indiate the relative concentrations of the corresponding metabolite in each group under study. **(F)** Bubble diagram of significantly differed pathways. The numbers are in accord with [Table 3](#T3){ref-type="table"} and representing filtered pathways. **(G)** Bar plot for metabolite sets enrichment. The bar length represent fold enrichment and the color legend indicating *p*-value.](fmicb-10-00177-g005){#F5}

###### 

Variations in metabolites driven by lysozyme treatment after 21-day supplementation.

  Metabolite                                         VIP       *P*-value^1^   m/z        RT (s)
  -------------------------------------------------- --------- -------------- ---------- ----------
  [L]{.smallcaps}-Glutamine                          1.57525   0.004859       129.0654   93.046
  Creatine                                           2.59744   0.015554       132.0767   363.362
  Triethanolamine                                    1.20796   0.008983       150.1116   163.715
  1,3,5-Trihydroxybenzene                            1.5075    0.016108       168.0651   430.955
  [L]{.smallcaps}-Arginine                           2.26854   0.029494       175.1185   523.8465
  *N*-Acetyl-[D]{.smallcaps}-glucosamine             6.81211   0.044037       204.0863   417.33
  Argininosuccinic acid                              3.1334    0.035875       291.1294   457.334
  *S*-Methyl-5′-thioadenosine                        3.56887   0.046785       298.0957   67.02
  2′-*O*-methylcytidine                              1.66055   0.038591       324.0581   436.676
  [D]{.smallcaps}-Lactose                            31.52     0.038208       343.1225   399.4185
  Guanosine 5′-diphosphate (GDP)                     7.40217   0.029233       444.03     439.483
  ADP-ribose                                         2.9509    0.00208        560.0759   408.2855
  GDP-[L]{.smallcaps}-Fucose                         4.36646   0.026333       590.0863   439.1075
  Reduced nicotinamide adenine dinucleotide (NADH)   1.03812   0.017532       666.1275   390.424
  Stachyose                                          1.7266    0.02151        689.2069   457.576
  Benzoic acid                                       1.38217   0.02887602     121.0301   106.4585
  Citraconic acid                                    1.77585   0.01178885     129.0199   423.3335
  Capric acid                                        1.31793   0.00196452     171.1386   47.718
  *cis*-Aconitate                                    2.4721    0.01471209     173.009    423.336
  Maleic acid                                        1.7544    0.0143732      175.0245   352.1695
  [L]{.smallcaps}-Gulonic gamma-lactone              1.58526   0.001417626    177.0399   144.86
  2′-Deoxyuridine                                    1.60415   0.02979523     227.0662   120.194
  Succinate                                          2.91345   0.003600293    235.0448   352.1695
  [D]{.smallcaps}-Ribose 5-phosphate                 1.19978   0.04074732     289.0314   453.871
  *N*-Acetylneuraminic acid                          1.00284   0.01040533     290.0861   341.944
  Sucrose                                            1.26721   0.02556989     323.0962   429.7805
  Estrone 3-sulfate                                  1.99979   0.03466092     349.1089   24.8065
  Nervonic acid                                      1.14023   0.01313373     365.3397   40.47
  Uridine 5′-diphosphate (UDP)                       2.21374   0.01324003     402.9919   459.15
  Uridine 5′-triphosphate (UTP)                      1.95969   0.03726824     482.9569   430.288
  ADP-ribose                                         1.48413   0.003672366    558.0596   408.6775
  UDP-[D]{.smallcaps}-glucose                        18.7714   0.04512712     565.0448   429.7805
  UDP-[D]{.smallcaps}-glucuronate                    7.01253   0.03221274     579.0232   459.51
  GDP-[L]{.smallcaps}-fucose                         4.89825   0.01274555     588.0709   439.5195

1

P

-values are from one-way ANOVA test.

To explore the biological functions of these metabolic makers, metabolite-set enrichment analysis was performed via MetaboAnalyst v4.0 ([Figure 5G](#F5){ref-type="fig"}). Pathway topology analysis using relative centrality revealed nine significantly different (*P* \< 0.05) enriched pathways ([Figure 5F](#F5){ref-type="fig"}), including alanine, aspartate, and glutamate metabolism, pyrimidine metabolism, arginine and proline metabolism, galactose metabolism, ascorbate and aldarate metabolism, amino sugar and nucleotide sugar metabolism, starch and sucrose metabolism, purine metabolism, and the citrate cycle ([Table 3](#T3){ref-type="table"}).

###### 

Most enriched pathways of metabolic makers (TOP 10).

  No.   Pathways                                      Total   Expected   Hits   *P*-value^1^   Impact
  ----- --------------------------------------------- ------- ---------- ------ -------------- --------
  1     Alanine, aspartate and glutamate metabolism   24      0.279      3      0.002          0.207
  2     Pyrimidine metabolism                         60      0.698      4      0.005          0.050
  3     Arginine and proline metabolism               77      0.896      4      0.011          0.174
  4     Galactose metabolism                          41      0.477      3      0.011          0.034
  5     Ascorbate and aldarate metabolism             45      0.523      3      0.014          0.098
  6     Amino sugar and nucleotide sugar metabolism   88      1.024      4      0.017          0.212
  7     Starch and sucrose metabolism                 50      0.582      3      0.019          0.300
  8     Purine metabolism                             92      1.070      4      0.020          0.023
  9     Citrate cycle (TCA cycle)                     20      0.233      2      0.022          0.070
  10    Butanoate metabolism                          40      0.465      2      0.078          0.38

1

P

-values are from Hypergeometric Test.

To further investigate the correlation between milk metabolic indicators and the altered gut microbiome driven by lysozyme treatment, Spearman's correlation coefficients between significantly different metabolites and major genera were also calculated and visualized with heat map ([Supplementary Figure 4A](#SM1){ref-type="supplementary-material"}). For instance, [L]{.smallcaps}-glutamine showed significant positive correlations with *Lactobacillus, Ruminococcus* 1 and *Lachnospiraceae MK4A136* group. [L]{.smallcaps}-Arginine showed significant negative correlations with *Sphaerochaeta, Prevotella* 1, *Pseudobutyrivibrio*, and *Prevotella 9*. Moreover, lysozyme-supplementation mediated associations among milk composition, serum immunity, and gut microbiota were also summarized and bacteria showed significant impact on both serum biomarkers and milk metabolic makers were filtered ([Supplementary Figure 4B](#SM1){ref-type="supplementary-material"}).

Discussion
==========

The application of antibiotics in feeds at subtherapeutic levels could improve performance and overall health and is used extensively throughout the swine industry ([@B37]). Because of the rising concerns about antibiotic resistance and human health, many countries including China (starting in 2020), America, and the European Union banned the use of antibiotics in swine production ([@B36], [@B37]; [@B38]). Thus, research into alternatives is important for the future development of the livestock industry. Recent studies also revealed that maternal diets and gut microbiota could directly affect the offspring development early in life ([@B8]; [@B6]; [@B55]).

Sows treated with probiotic combinations resulted in improved microbiota diversity in neonatal piglets ([@B52]). In the current study, microbial diversity evidenced by the Shannon index showed a significant reduction in the 1.0 kg/t lysozyme-treated group (*p* = 0.0014, [Figure 1A](#F1){ref-type="fig"}). No differences in microbial richness were found. Previous studies reported that lysozyme could be effective against a wide range of gastrointestinal pathogens, such as *Listeria monocytogenes, Clostridium perfringens, Candida* spp., and *Helicobacter pylori in vitro* ([@B4]; [@B61]). Reduced microbial diversity indicating a better intestinal condition and physiological preparation for parturition ([@B52]; [@B6]). Furthermore, *Spirochaetes, Euryarchaeota*, and *Actinobacteria* significantly increased but *Firmicutes* showed a remarkable reduction in the 1.0 kg/t group compared with the control group. As previous researches reported, ETEC is the major causative agent of diarrhea in weaned pigs, which attaches to the intestinal mucosa, leading to compromised barrier function and malabsorption of large molecules ([@B17]; [@B34]; [@B23]). Higher concentrations of lysozyme in milk confer enteric health benefits and prevents ETEC infections in young animals ([@B20]; [@B34]; [@B9]; [@B23]). Hence, pathogenic bacteria enriched species in this study were also concerned. For instance, *Escherichia coli* showed a dramatically dose-response reduction in both the 0.5 kg/t and 1.0 kg/t lysozyme-treated groups ([Figure 1F](#F1){ref-type="fig"}). Other reported pathogens which could be against by lysozyme like *Helicobacter* also reduced in lysozyme treated groups but it was not significant ([Figure 4E](#F4){ref-type="fig"}). Conventional probiotics like *Lactobacillus amylovorus* and *Treponema bryantii* significantly increased in the 0.5 kg/t and 1.0 kg/t groups ([Figure 1F](#F1){ref-type="fig"}). *Lactobacillus* is reported to improve the intestinal environment and activate intestinal mucosal immunity in many species, resulting in enhanced SIgA production of the innate immune system, which is essential for the prevention of fimbriae-mediated colonization and the maintenance of intestinal barrier function ([@B59]; [@B15]). In summary, lysozyme addition rebuilt sow's gut microbiota to better composition identified by reduced richness of *E. coli* and increased abundance of *Lactobacillus amylovorus*.

For microbial metabolic functions, results showed that pyrimidine metabolism, purine metabolism, and amino acid related enzymes were significantly upregulated in the 1.0 kg/t lysozyme-treated group. Lysozyme may promote the shift to greater amino acid and nucleotide metabolism in gut microbial communities ([Figure 2](#F2){ref-type="fig"}). These metabolic functional changes in gut microbiota are revealed for the first time. Besides, lysozyme mediated dose-dependent changes in gut microbial metabolic phenotypes. For instance, higher lysozyme levels in formula diet significantly down-regulated the richness of Gram-positive bacteria. Our findings confirmed that lysozyme has a robust antimicrobial activity against Gram-positive bacteria, and to a much lesser degree, against Gram-negative bacteria ([@B30]). Lysozyme supplementation also significantly increased biofilm formation in the lysozyme-treated groups ([Figure 3G](#F3){ref-type="fig"}). Formation of microbial community biofilms was reported to be closely related to drug resistance and pathogenesis ([@B1]; [@B25]). The mechanism of these changes in metabolic phenotypes also remain unknown. In conclusion, lysozyme supplementation also shifted the metabolic functions and phenotypes of sow's gut microbiota.

Lysozyme is an important modulator in innate immunity and plays a crucial role in preventing intestinal inflammation ([@B22]; [@B39]; [@B40]). Mammalian Paneth cells are able to secrete lysozyme via secretory autophagy to maintain intestinal homeostasis to against pathogenic infections ([@B3]). For serum immunity, serum IgA levels were significantly reduced by increased lysozyme levels. Meanwhile, serum IgM was significantly higher in the 1.0 kg/t group compared with the control group. Lower serum IgA indicates a lower risk of allergy in the postnatal period, which differs from mucosal SIgA ([@B16]; [@B14]). IgM is an important anti-inflammatory factor and increased IgM also indicating a better immune status ([@B51]). What is more, serum ALT levels were also significantly down-regulated by lysozyme treatment (*p* = 0.001). ALT was reported to be a liver-specific enzyme that is released into serum following acute liver injury ([@B44]). Here, down-regulated serum ALT levels also indicate improved overall health ([@B44]). In short, lysozyme supplementation could benefit sows with better immune status via down-regulating serum ALT and IgM and reducing serum IgA.

To determine the effect of dietary lysozyme on sow's milk metabolites, untargeted LC--MS/MS were used to explore the metabolome of all groups. Results showed that metabolites including [L]{.smallcaps}-glutamine, succinate, triethanolamine, and [L]{.smallcaps}-arginine were significantly up-regulated by lysozyme supplementation. It should be noted that [L]{.smallcaps}-glutamine could enhance tight junction integrity and proliferation of intestinal porcine epithelial cells ([@B43]; [@B54], [@B53]), which is essential for normal intestinal development. Also, succinate is a metabolite that improves glycemic control through the activation of intestinal gluconeogenesis ([@B11]). Our previous work revealed that ethanolamine can enhance intestinal function by altering gut microbiome and mucosal anti-stress capacity ([@B63], [@B64]). Moreover, [L]{.smallcaps}-arginine was also shown to play a significant role in shaping the gut microbiota and innate immunity of piglets, thus improving gut development and protecting against pathogenic infection ([@B21]; [@B41]; [@B58]). Further, pathway enrichment and topology analysis of these metabolites revealed nine significantly different (*P* \< 0.05) enriched pathways ([Figure 5F](#F5){ref-type="fig"}) including alanine, aspartate, and glutamate metabolism and pyrimidine metabolism, arginine, and proline metabolism, which also further supports the conclusions noted above. To sum up, dietary lysozyme supplementation significantly altered the milk composition of sows, which may benefit the development of their offspring ([@B8]; [@B6]; [@B55]).

Associations among gut microbiota, serum immunity and milk metabolites were also explored for the first time ([Supplementary Figure 4B](#SM1){ref-type="supplementary-material"}). This research proved that lysozyme has widespread influence on sow health including gut microbiota, serum immunity, and milk composition for the first time. In conclusion, lysozyme supplementation could effectively improve the composition, metabolic functions and phenotypes of sow's gut microbiota and it also benefit sows with better immune status and milk composition. This research could provide theoretical support for further application of lysozyme in promoting animal gut health and prevent pathogenic infections in livestock production.
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